Multidimensional in vivo metabolic flux analyses: Resolving immune cells based on in vivo metabolic phenotypes
The project aims to develop a novel nutrient uptake assay for analyzing immune cell metabolism in vivo, enhancing immunotherapy design for solid tumors through detailed metabolic insights.
Projectdetails
Introduction
The development of better immunotherapies is being hindered by our lack of understanding about immune cell metabolism in vivo at the sites of disease. We know that immune cell metabolism is pivotal in controlling immune function.
Importance of Immune Cell Metabolism
For instance, disrupting Natural Killer cell metabolism prevents them from killing cancer cells. Cellular immunotherapies for diseases like solid cancer are underperforming, and one central reason for this is the metabolic pressure exerted on immune cells in solid tumors.
Current Challenges
The core problem is that we cannot currently measure the metabolism of immune cells at the site of disease. As a result, the biopharma industry is ill-equipped to design immunotherapies that are effective at these sites in the face of the metabolic stress.
Project Overview
My ERC-CoG project (DC_Nutrient) has developed a new type of nutrient uptake assay with single-cell resolution that can be used to probe metabolism in vivo. This is highly informative because the uptake of nutrients is the first limiting step for cellular metabolism.
Methodology
The core advance in our approach is to use bioorthogonal chemistry to attach a fluorophore to the nutrient after it has been transported into the cell. This bypasses all the pitfalls and failings of previous attempts to develop such assays using fluorophore tags.
Proof of Concept
This PoC will advance this technology to simultaneously measure the uptake of 3 separate nutrients into immune cells at the site of disease, all with single-cell resolution. Combined with an in vivo measurement of protein translation, this will provide 4 dimensions of metabolic flux analysis for each cell analyzed by multiparametric flow cytometry.
Expected Impact
This innovative idea will provide a licensable assay technology that will be of high value to the biopharma industry as it will enable preclinical mouse studies to gain a detailed understanding of the metabolic changes occurring in immune cells at the site of disease. This technology will drive innovation towards metabolically enhanced immunotherapies.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-6-2023 |
Einddatum | 30-11-2024 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Spatial Quantification of Cellular Metabolism in the Tumor Immune MicroenvironmentThis project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment. | ERC Starting... | € 1.497.756 | 2023 | Details |
Capturing tumoral drug metabolism by Cells In the Tissue Environment using spatial pharmacometabolomicsThe CITE project aims to develop innovative analytical technologies to study intratumoral drug metabolism in pancreatic cancer, enhancing understanding of treatment resistance mechanisms. | ERC Starting... | € 2.481.640 | 2024 | Details |
Intercellular trading in nucleotide metabolism: an emerging targetThis project aims to identify nucleotide sources and metabolic interactions in cancer and stromal cells using single-cell multi-omics to develop targeted therapies against nucleotide-dependent tumors. | ERC Starting... | € 1.450.000 | 2022 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC Consolid... | € 1.993.875 | 2023 | Details |
Single-Cell Metabolomics for Drug Discovery and DevelopmentThe project aims to commercialize single-cell metabolomics technology to enhance drug safety by revealing off-target effects and metabolic responses in drug candidates. | ERC Proof of... | € 150.000 | 2022 | Details |
Spatial Quantification of Cellular Metabolism in the Tumor Immune Microenvironment
This project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment.
Capturing tumoral drug metabolism by Cells In the Tissue Environment using spatial pharmacometabolomics
The CITE project aims to develop innovative analytical technologies to study intratumoral drug metabolism in pancreatic cancer, enhancing understanding of treatment resistance mechanisms.
Intercellular trading in nucleotide metabolism: an emerging target
This project aims to identify nucleotide sources and metabolic interactions in cancer and stromal cells using single-cell multi-omics to develop targeted therapies against nucleotide-dependent tumors.
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
Single-Cell Metabolomics for Drug Discovery and Development
The project aims to commercialize single-cell metabolomics technology to enhance drug safety by revealing off-target effects and metabolic responses in drug candidates.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samplesThe NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs. | EIC Transition | € 2.499.999 | 2025 | Details |
The critical shift to single-cell formats in functional analyses of living cellsSamplix is developing Xplore, a cost-effective single-cell analyser and sorter to enhance immune cell analysis, supporting faster development of personalized therapies for serious diseases. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Magnetic Resonance at the Scale of a CellThe HyperCell project aims to revolutionize cell research by developing a non-invasive benchtop tool for single-cell metabolic analysis, enhancing understanding of diseases and treatment responses. | EIC Transition | € 1.998.750 | 2024 | Details |
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samples
The NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs.
The critical shift to single-cell formats in functional analyses of living cells
Samplix is developing Xplore, a cost-effective single-cell analyser and sorter to enhance immune cell analysis, supporting faster development of personalized therapies for serious diseases.
Magnetic Resonance at the Scale of a Cell
The HyperCell project aims to revolutionize cell research by developing a non-invasive benchtop tool for single-cell metabolic analysis, enhancing understanding of diseases and treatment responses.